Semaglutide (Ozempic, Wegovy, Rybelsus)

Mechanism of Action

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to endogenous human GLP-1(7-37). The molecule incorporates two key modifications that confer its extended pharmacokinetic profile: an amino acid substitution at position 8 (Aib replacing Ala) that renders it resistant to degradation by dipeptidyl peptidase-4 (DPP-4), and a C-18 fatty diacid chain attached via a linker at position 26 (Lys) that enables non-covalent binding to serum albumin.1 These modifications extend the plasma half-life to approximately 165–184 hours (~7 days), permitting once-weekly subcutaneous administration.2

Upon binding to the GLP-1 receptor on pancreatic beta cells, semaglutide potentiates glucose-dependent insulin secretion via the incretin effect, while simultaneously suppressing inappropriately elevated glucagon release from alpha cells. This dual pancreatic action results in improved glycemic control without significant intrinsic hypoglycemia risk when used as monotherapy.13 Beyond the pancreas, semaglutide activates GLP-1 receptors in the gastrointestinal tract to slow gastric emptying, which attenuates postprandial glucose excursions and contributes to early satiety.4

The weight-loss efficacy of semaglutide is predominantly mediated through central mechanisms. GLP-1 receptors in the hypothalamic arcuate nucleus and other appetite-regulatory centers are activated by semaglutide, resulting in reduced hunger, decreased food intake, and altered food preferences away from high-fat, energy-dense foods.5 Neuroimaging studies have confirmed that semaglutide reduces activity in brain regions associated with appetite and reward processing, providing a neurobiological basis for the clinically observed reduction in caloric intake of approximately 24–35%.45

Evidence Summary

Glycemic Control (SUSTAIN Program)

The SUSTAIN clinical trial program evaluated semaglutide (0.5 mg and 1.0 mg weekly) across multiple phase 3 RCTs in patients with type 2 diabetes. In SUSTAIN-6, a cardiovascular outcomes trial enrolling 3,297 patients, semaglutide demonstrated a statistically significant 26% reduction in the primary composite endpoint of major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) versus placebo (HR 0.74; 95% CI 0.58–0.95; p<0.001 for noninferiority).1 Mean HbA1c reductions of 1.0–1.8% were consistently observed across SUSTAIN trials, with superiority demonstrated over sitagliptin, exenatide extended-release, dulaglutide, and insulin glargine.2

Weight Management (STEP Program)

The STEP (Semaglutide Treatment Effect in People with Obesity) trial program evaluated semaglutide 2.4 mg weekly for chronic weight management. In STEP 1, a landmark double-blind RCT of 1,961 adults with BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity), participants receiving semaglutide 2.4 mg achieved a mean body weight reduction of 14.9% versus 2.4% with placebo at 68 weeks (estimated treatment difference −12.4 percentage points; p<0.001).5 Notably, 86.4% of semaglutide-treated participants achieved at least 5% weight loss, and 69.1% achieved at least 10%, compared to 31.5% and 12.0% with placebo, respectively.5

Oral Semaglutide (PIONEER Program)

The PIONEER trial program established the efficacy of oral semaglutide (Rybelsus) at doses of 7 and 14 mg daily. Oral semaglutide uses a co-formulation with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that facilitates gastric absorption. In PIONEER 6, a cardiovascular safety trial, oral semaglutide demonstrated noninferiority to placebo for MACE (HR 0.79; 95% CI 0.57–1.11), with a numerically favorable but non-significant reduction in cardiovascular events.6

Cardiovascular Risk Reduction (SELECT Trial)

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity), a landmark double-blind RCT enrolling 17,604 adults aged 45 years or older with pre-existing cardiovascular disease and BMI of 27 or greater but without diabetes, demonstrated that semaglutide 2.4 mg weekly reduced the primary composite MACE endpoint by 20% versus placebo (HR 0.80; 95% CI 0.72–0.90; p<0.001) over a mean follow-up of 39.8 months.7 This trial established semaglutide as the first GLP-1 receptor agonist with a dedicated cardiovascular indication independent of diabetes status, and it led to an expanded FDA indication for cardiovascular risk reduction in 2024.7

Primary Uses

• Type 2 diabetes mellitus (Ozempic, 0.5–1.0 mg/week subcutaneous; Rybelsus, 7–14 mg/day oral): As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. FDA-approved December 2017.2
• Chronic weight management (Wegovy, 2.4 mg/week subcutaneous): For adults with BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia). FDA-approved June 2021.5
• Cardiovascular risk reduction (Wegovy, 2.4 mg/week subcutaneous): To reduce the risk of MACE in adults with established cardiovascular disease and overweight or obesity. FDA indication expanded March 2024, based on the SELECT trial.7

Common Stacks & Synergies

Semaglutide is frequently used in combination with other therapies depending on the clinical indication. The following combinations are evidence-supported and commonly employed in clinical practice:

• Metformin + Semaglutide (T2D): The most common background therapy combination for type 2 diabetes. Metformin addresses hepatic glucose output and improves insulin sensitivity, while semaglutide enhances incretin-mediated insulin secretion and suppresses appetite. All SUSTAIN trials permitted metformin as background therapy.12
• Structured exercise program + Semaglutide (weight management): In the STEP trials, all participants received lifestyle intervention counseling (500 kcal/day deficit plus 150 minutes/week of physical activity). Combined pharmacotherapy and behavioral intervention yields greater and more sustained weight loss than either alone.5
• SGLT2 inhibitor + Semaglutide (T2D with cardiorenal benefit): Emerging practice combines GLP-1 receptor agonists with SGLT2 inhibitors for complementary cardiovascular and renal protection, though dedicated combination outcome trials are limited.

For detailed combination protocols and titration schedules, see our Protocols page.

Preparation & Administration

Subcutaneous Injection (Ozempic / Wegovy)

Semaglutide for injection is supplied as a clear, colorless solution in a pre-filled, multi-dose or single-dose disposable pen. No reconstitution or dilution is required.

• Injection sites: Abdomen (at least 2 inches from navel), thigh (front or outer aspect), or upper arm (back of arm). Rotate injection sites with each dose to reduce the risk of lipodystrophy.
• Pen priming: For new pens, attach a new needle and prime by dialing 0.25 mg on the Ozempic pen (or following the specific pen instructions for Wegovy), then press the injection button until a drop appears at the needle tip. This confirms proper flow.
• Injection technique: Clean the skin with an alcohol swab. Pinch the skin if needed, insert the needle at a 90-degree angle, press the dose button completely, and hold for at least 6 seconds (Ozempic) or 10 seconds (Wegovy) before withdrawing to ensure full dose delivery.
• Timing: Inject once weekly on the same day each week, at any time of day, with or without meals. The injection day can be changed if needed, provided the interval between doses is at least 48 hours.

For detailed injection technique instruction and safety guidance, see our Injection Safety guide.

Oral Administration (Rybelsus)

• Take on an empty stomach upon waking.
• Swallow whole with no more than 4 oz (120 mL) of plain water only.
• Wait at least 30 minutes before eating, drinking anything other than plain water, or taking other oral medications.
• Do not split, crush, or chew the tablet. The SNAC absorption enhancer requires the intact tablet to function properly.

Side Effects & Adverse Events

Common Adverse Reactions (≥5%)

Gastrointestinal adverse events are the most frequently reported side effects and are the primary reason for treatment discontinuation. Most GI events are mild to moderate and occur during dose escalation, tending to diminish over time.58

• Nausea: 20–44% (most common; highest with 2.4 mg dose)
• Diarrhea: 15–30%
• Vomiting: 6–24%
• Constipation: 10–24%
• Abdominal pain: 6–20%
• Dyspepsia: 5–9%
• Headache: 10–14%
• Fatigue: 5–11%
• Injection site reactions: 3–6% (subcutaneous formulations)

Serious Adverse Events

• Pancreatitis: Rare (reported in <1% of participants in clinical trials). Discontinue immediately if pancreatitis is suspected (persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting).8
• Gallbladder events: Cholelithiasis (1.5–5%) and cholecystitis have been reported at higher rates than placebo, particularly at the 2.4 mg dose.5
• Hypoglycemia: Low risk as monotherapy (<1%). Risk increases significantly when combined with insulin or sulfonylureas (up to 5–10%). Dose reduction of concomitant secretagogue or insulin is recommended.8
• Diabetic retinopathy complications: Observed in SUSTAIN-6 (HR 1.76; 95% CI 1.11–2.78), likely related to rapid glucose improvement in patients with pre-existing retinopathy.1
• Acute kidney injury: Reported primarily in the setting of severe dehydration from GI adverse events. Monitor renal function in patients with renal impairment.
• Thyroid C-cell tumors: Observed in rodent carcinogenicity studies at clinically relevant exposures. Relevance to humans is uncertain. See Boxed Warning above.8
• Suicidal ideation: Post-marketing reports have emerged; FDA is evaluating. Patients should be monitored for mood changes.

Drug Interactions

Semaglutide slows gastric emptying, which may affect the rate of absorption of concomitantly administered oral medications. While studies have not shown clinically meaningful pharmacokinetic interactions for most tested drugs, the following interactions warrant clinical attention:8

• Oral medications with narrow therapeutic indices: Delayed gastric emptying may affect absorption kinetics. Exercise caution with drugs such as warfarin, levothyroxine, and oral contraceptives. Monitor INR more frequently when initiating or titrating semaglutide in patients on warfarin.
• Insulin and sulfonylureas: Concurrent use increases the risk of hypoglycemia. Consider reducing the dose of insulin or sulfonylurea when initiating semaglutide.8
• Other GLP-1 receptor agonists: Co-administration has not been studied and is not recommended due to potential for additive GI effects and unknown safety profile.
• Oral semaglutide (Rybelsus) specific: The SNAC absorption enhancer may interact with proton pump inhibitors (PPIs). In pharmacokinetic studies, omeprazole increased semaglutide exposure by approximately 34% when co-administered. Clinical significance is uncertain, but awareness is recommended.6

Storage & Handling

Subcutaneous Pens (Ozempic / Wegovy)

• Before first use: Refrigerate at 36–46°F (2–8°C). Do not freeze. Do not use if the product has been frozen.
• After first use: Store at room temperature (59–86°F / 15–30°C) or refrigerated for up to 56 days (Ozempic) or 28 days (Wegovy). Discard after this period regardless of remaining volume.
• Protect from light: Keep the pen cap on when not in use. Do not store with a needle attached.
• Do not use if the solution appears cloudy, discolored, or contains particles.

Oral Tablets (Rybelsus)

• Store at room temperature, 68–77°F (20–25°C); excursions to 59–86°F (15–30°C) are permitted.
• Keep in the original blister package to protect from moisture.
• Handle with dry hands when removing from blister.

Legal & Regulatory Status

• United States (FDA): Approved. Ozempic (subcutaneous, T2D) approved December 2017. Rybelsus (oral, T2D) approved September 2019. Wegovy (subcutaneous, weight management) approved June 2021. Wegovy cardiovascular indication expanded March 2024.78
• European Union (EMA): Approved. Ozempic authorized February 2018. Wegovy authorized January 2022. Rybelsus authorized April 2020.
• Prescription status: Prescription only in all approved markets. Semaglutide is not a controlled substance.
• Manufacturer: Novo Nordisk A/S (Bagsværd, Denmark).
• Compounding: Due to intermittent supply shortages, compounded semaglutide has been dispensed under FDA enforcement discretion during shortage periods. The FDA has issued guidance on compounded GLP-1 receptor agonists, and legal status of compounded versions is subject to ongoing regulatory updates. Compounded semaglutide is not FDA-approved and may carry additional risks.

Open Questions

Despite the robust evidence supporting semaglutide, several clinically important questions remain under active investigation:

• Long-term weight regain after discontinuation: The STEP 1 extension study demonstrated that participants regained approximately two-thirds of lost weight within one year of stopping semaglutide, raising questions about optimal treatment duration and the necessity of indefinite therapy for weight maintenance.9
• Optimal duration of therapy: Neither the diabetes nor the obesity clinical programs have established a recommended stopping point. Whether long-term (multi-decade) continuous therapy is safe and effective remains unknown.
• Cardiovascular benefit mechanism: The SELECT trial confirmed cardiovascular benefit, but the relative contributions of weight loss, direct anti-inflammatory effects, improved endothelial function, and other pleiotropic mechanisms are not fully delineated.7
• Cancer risk with long-term use: The rodent thyroid C-cell tumor signal has not been confirmed in humans, but long-term observational data remain limited. Ongoing pharmacovigilance studies and registries are monitoring for thyroid and pancreatic cancer signals.
• Lean mass preservation: Weight loss with GLP-1 receptor agonists includes loss of both fat and lean body mass. The optimal role of exercise prescriptions and protein intake targets during semaglutide therapy for lean mass preservation is an area of active research.
• Comparative effectiveness with tirzepatide: Head-to-head trials comparing semaglutide with tirzepatide (a dual GIP/GLP-1 receptor agonist) for weight management and cardiovascular outcomes are anticipated but not yet published as of April 2026.